Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01458600 |
| Other study ID # |
2005 02 23 |
| Secondary ID |
2005-000832-26 |
| Status |
Completed |
| Phase |
Phase 4
|
| First received |
October 19, 2011 |
| Last updated |
February 23, 2016 |
| Start date |
September 2006 |
| Est. completion date |
February 2016 |
Study information
| Verified date |
February 2016 |
| Source |
Region Skane |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Sweden: Medical Products Agency |
| Study type |
Interventional
|
Clinical Trial Summary
AGO study - adjuvant treatment, with NSAID, of endocrine ophthalmopathy in Graves´ disease
Background - Already at diagnosis of Graves disease approximately 98% of the patients have
morphological changes of the retrobulbar tissue concordant with ophthalmopathy. Factors
known to induce clinical symptoms of ophthalmopathy are mainly unknown. An interesting
observation is that a patient with stable and inactive Graves´ disease developed
ophthalmopathy when treated with a glitazone due to diabetes type 2. Glitazones have been
shown to increase differentiation of orbital preadipocytes to mature adipocytes. Glitazones
are PPAR-gamma agonists and recently diclofenac have been shown to interact with PPAR-gamma
in physiological concentrations. Other non-steroidal antiinflammatory drugs, NSAID, like
indomethacin lack this effect. In addition, diclofenac inhibit synthesis of prostaglandins
which also may be of importance because the natural ligand to PPAR-gamma is prostaglandin J.
Inflammation and adipogenesis are hallmarks of the pathological process in Graves
ophthalmopathy and NSAID like diclofenac may affect both. There is only one earlier study
demonstrating effects of NSAID (indomethacin) in 7 patients with effects on soft tissue
symptoms, eye muscle symptoms and eye protrusion.
Aim - to investigate if diclofenac can prevent ophthalmopathy and/or progress of
ophthalmopathy.
Specific aims:
1. To study the frequency of clinical ophthalmopathy in Graves´ disease after 12 months
treatment with or without diclofenac.
2. To study the frequency of progress of clinical signs and symptoms in ophthalmopathy
after 12 months treatment with or without diclofenac.
3. To study the frequency of optic neuropathy in clinical ophthalmopathy after 12 months
treatment with or without diclofenac.
Study plan and randomisation -
150 patients with newly diagnosed Graves´disease without ophthalmopathy will be treated with
anti-thyroid drugs and L-thyroxin (block and replace) according to clinical routine for 18
months. These patients will be randomized to diclofenac 50 mg twice daily or not for 12
months.
Description:
Adjuvant treatment of Graves´ ophthalmopathy with NSAID (aGO study)
1. Background.
When performing MRI / CT / ultrasound of the orbital room 98 % of the patients with
Graves´ thyrotoxicosis exhibit changes of ophthalmopathy without clinical symptoms of
endocrine ophthalmopathy (Burch 1993). Thus, almost all patients with Graves´ disease
are at risk to develop clinical ophthalmopathy. Tobacco exposition and treatment with
radioiodine ar known factors that trigger ophthalmopathy but other factors are poorly
defined. However it is well known that both environmental and genetic factors is of
importance because monozygotic twins show a concordance of 20 - 50 %. One interesting
observation is a patient with inactive and stable Graves´ ophthalmopathy who developed
clinical ophthalmopathy when treated with pioglitazone due to type 2 diabetes (Starkey
2003). One pathogenic mechanism in Graves´ ophthalmopathy is increased orbital
adipogenesis and glitazones are known to increase the volume of subcutaneous adipose
tissue. Orbital fibroblasts from patients with ophthalmopathy have been shown to
differentiate to adipocytes in response to rosiglitazone (Valyasevi 2002). Glitazones
are PPAR-gamma agonists and it could be of interest to study effects of PPARgamma
antagonists in endocrine ophthalmopathy. Diclofenac has been shown to interact with
PPAR-gamma in physiological concentrations and to antagonise PPAR-gamma mediated
effects like adipogenesis of the preadipocyte cell line 3T3-L1(Adamsson 2002,
Vondrichova 2007). In addition diclofenac is a well-known inhibitor of cyclooxygenases
with effects on the synthesis of prostaglandins in for example fibroblasts, lymphocytes
and monocytes. The natural ligand for PPAR-gamma is prostaglandin J (Forman 1995). To
conclude, NSAID like diclofenac may affect both synthesis of prostaglandins and
concomittantly antagonise the effects of the natural ligand to PPAR-gamma,
prostaglandin J2. We have recently demonstrated upregulation of immediate early genes,
including COX-2, with important functions in adipogenesis in patients with severe
ophthalmopathy (Lantz 2005). Previously there is only one study published on treatment
of ophthalmopathy with NSAID ,indometacin (Amemia 1982). Although only 7 patients were
studied there were effects on soft tissue symptoms, eye protrusion and eye muscle
symptoms. Due to the knowledge of retrobulbar morphological changes in patients with
Graves´ thyrotoxicosis without clinical ophthalmopathy it may be of importance to
interact as early as possible. We therefore plan to start a randomised single-blind
study where patients will receive diclofenac for 12 months in parallel with the
standard treatment for thyrotoxicosis.
2. Trial design
The trial is a multi-center (Malmö and Stockholm), controlled, single-blind design and
the subjects are randomised to thyrostatics with and without diclofenac by a body
independent from the study The total duration of the study is 24 months with 12 months
treatment with or without diclofenac in addition to regular treatment for
thyrotoxicosis. The follow up period will be 12 months. Decision of the main treatment
of thyrotoxicosis is based on clinical terms according to routines in Malmö and
Stockholm and is given according to the protocol of TT96. Patients are randomised for
adjuvant therapy with or without diclofenac after choice of main treatment for
thyrotoxicosis.
2.1 Monitoring
The study will be monitored by a science nurse with formal education in monitoring
clinical trials.
3. Objectives
The primary objective
To find out if diclofenac can prevent development of ophthalmopathy in patients with Graves´
disease.
The secondary objectives are:
1. Determine the activity at diagnosis of ophthalmopathy
2. Determine the time from thyrotoxicosis to ophthalmopathy
3. Determine the frequency of patients with corticosteroid requiring ophthalmopathy
3.1 Endpoints
The objectives of the trial will be examined by the following endpoints:
Efficacy
Primary endpoint:
The frequency of ophthalmopathy after 24 months as judged by the following clinical
signs:.
Optic nerve dysfunction 0. No 1. Yes Eye-lid edema 0. No 1. Yes Chemosis 0. No 1. Yes
Conjunctival injection 0. No 1. Yes Exophthalmos 0. No 1. Yes Hertel - base right left
Eye muscle dysfunction 0. No 1. Yes Corneal ulcers 0. No 1. Yes
Summa:
Ophthalmopathy is present if the patient has one sign or more.
Secondary endpoints:
I. Activity of ophthalmopathy as judged by clinical activity score (CAS)
Spontaneous retrobulbar pain 0. No 1. Yes Painful eye-movements 0. No 1. Yes Eye-lid
erythema 0. No 1. Yes Conjunctival injection 0. No 1. Yes Chemosis 0. No 1. Yes
Swollenness of caruncula 0. No 1. Yes Eye-lid edema or swollenness 0. No 1. Yes
Sum:
II. The time from thyrotoxicosis to ophthalmopathy.
III. The frequency of corticosteroid requiring ophthalmopathy. Criteria for start of
steroid treatment are: 1. Risk of corneal ulcers with or without exophthalmos 2. Double
vision within 30 degrees 3. Optic nerve dysfunction.
3.2 Treatment of subjects
All patients that fulfill the inclusion criteria and accept participation in the study
will after decision of main treatment for thyrotoxicosis be randomised to treatment
with or without diclofenac. Patients will receive diclofenac 50 mg 1x2 for 12 months in
addition to standard treatment of thyrotoxicosis according to the following routines.
Thyrostatics
Patients will receive p.o. methimazole (Thacapzol) 5 mg 3x2 supplemented with
L-thyroxine (Euthyrox) after 14 days, initially for the first two weeks 0.5x1, and
thereafter 1x1. If the patient react with allergic symptoms to methimazole, treatment
is changed to propylthiouracil (Tiotil) 50 mg 3x3. Adjustment of L-thyroxine is done
with help of thyroid laboratory parameters (TSH, fT4) and titration after clinical
response. The dose of thyrostatics is not reduced and if necessary on demand the dose
is increased. If necessary, a beta-blocker is used, primarily propranolol (Inderal) 40
mg 1x1-3 or metoprolol (Seloken) 50 mg 1x1-3 which can be increased depending of
patients response.
3.3 Measurement of laboratory parameters
All laboratory analyses will be performed at the department of Clinical Chemistry,
Malmö University Hospital and at the department of Clinical Chemistry Karolinska
University Hospital.
4. Rationale for treatment
Adjuvant treatment already at diagnosis of thyrotoxicosis has been chosen in the aim to
prevent clinical ophthalmopathy due to the fact that morphological changes of
ophthalmopathy in the orbital room exist in Graves´ thyrotoxicosis in up to 98% of the
patients without clinical symptoms. The long period of time for treatment with
diclofenac is justified by the knowledge that the majority of patients at risk for
developing ophthalmopathy exhibit clinical symptoms within 18 months.
5. Subjects
5.1 Number of patients
A total of 150 statistically analysable patients (the total number of patients included
will be 10% higher to compensate for loss of subjects) , with 75 in each treatment arm
will be included in the study.
6. Visits - summary
S = Screening tests, TSH, fT4, fT3, Thyroid Receptor antibodies (TRAK), Tissue Peroxidase
antibodies (TPO-ak), Hb, leukocytes, thrombocytes (trc), diff.-leukocytes, fasting
B-glucose, HbA1c, Calcium, Albumin, Sodium, Potassium, Creatinine, ASAT, ALAT, ALP, GT, Bil,
PK, APTT, U-iodine R = Routine tests, TSH, fT4, fT3, Hb, Creatinine R+ = Routine tests +
ASAT, ALAT, ALP, GT, Bil, TRAK, trc, leukocytes, diff. R++ = Routine tests + + Fasting
B-glucose, U-iodine B = Biobank samples according to GD2002 (serum, plasma, buffy coat) C =
Clinical control - vital signs, physical examination, weight, eye status O = Ophthalmologist
- eye status D = Dietary questionnaire
Time
-1 week S, B, C, O, D 0 week C 6 week R, C 3 months R+, B, C 6 months R, B, C 9 months R+,
B, C 12 months R++, B, C, O, D 15 months R+, B, C 18 months R, B, C 21 months R, B, C 24
months R++, B, C, O, D
6.1 Screening
Subjects attend to the first screening visit one week before randomisation. Before screening
the participants have been provided with written information of the trial. The subjects will
be informed, orally and in writing of their responsibilities / rights during the trial as
well as possible advantages / disadvantages of the trial. Subjects who wish to participate
will be asked to sign and date an Informed Consent Form prior to any trial-related activity.
Subjects will be allocated a subject number and the following will be performed and
recorded:
1. Assessment of inclusion and exclusion criteria
2. Demographic information
3. Thyroid history
4. General physical examination
5. Measurement of body weight
6. Vital signs
7. Blood sampling
8. Pregnancy test will be performed as per judgement of the investigator
9. Concomitant illness and medication.
10. Information and choice of the routine treatments for thyrotoxicosis
11. Actual eye status, performed by an ophthalmologist within 1 week
12. An appointment will be made for visit w0
6.2 Randomization visit, w0
Laboratory data and other information gathered at screening visit is reviewed and the final
decision regarding participation in the trial is taken.
The subject will now be randomised to adjuvant treatment with or without diclofenac. The
randomization procedure will be designed by an independent body.
7. Trial material
The trial is not performed in direct collaboration with the drug manufacturers.
9. Statistical considerations
The primary evaluation variable is the proportion of present or new cases of endocrine
ophthalmopathy. The null-hypothesis is that there is no differences between the two
treatment alternatives according to this proportion (H0:pi 1 = pi 2). The number of patients
in each group when performing a two-side significance test on the 5% level for different
demands on power and different values in the given proportions of the hypothesis is shown in
a separate diagram. With 72 patients in each group there is 80 % chance (power) to get
significant results if the real difference is 0.2. The hypothesis is tested with Mantel
Haenzels test and further analyses performed with logistic regression which take into
consideration the effect of prognostic factors.
